Eosinophilic myositis in calpainopathy: Could immunosuppression of the eosinophilic myositis alter the early natural course of the dystrophic disease?

Neuromuscular Disorders

Volumn 19, Issue 4, 2009, Pages 261-263

  Oflazer, Piraye Serdaroglu ^a   Gundesli, Hülya ^b   Zorludemir, Suzan ^c   Sabuncu, Tevfik ^d   Dincer, Pervin ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^d HARRAN UNIVERSITY   (Turkey)

Author keywords

Calpainopathy; Eosinophilic myositis; LGMD 2A; Muscular dystrophy

Indexed keywords

AZATHIOPRINE; CALPAIN 3; DYSTROPHIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; SARCOGLYCAN;

ANAMNESIS; ARTICLE; CALPAINOPATHY; CASE REPORT; CHILD; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; EOSINOPHIL MYOSITIS; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; PRIORITY JOURNAL; SCHOOL CHILD;

AZATHIOPRINE; CALPAIN; CHILD; CREATINE KINASE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EOSINOPHILIA-MYALGIA SYNDROME; EOSINOPHILS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; METHYLPHENAZONIUM METHOSULFATE; MUSCLE PROTEINS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MYOSITIS; PREDNISOLONE; TREATMENT OUTCOME;

EID: 63749115143     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.01.010     Document Type: Article

References (13)

1. Richard I., Broux O., Allamand V., et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 81 (1995) 27-40
2. Groen E.J., Charlton R., Barresi R., et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 130 (2007) 3237-3249
3. Tidball J.G., and Wehling-Henricks M. Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol 17 (2005) 707-713
4. Confalonieri P., Oliva L., Andreetta F., et al. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 142 (2003) 130-136
5. Darin N., Kroksmark A.K., Ahlander A.C., et al. Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 11 (2007) 353-357
6. Krahn M., Lopez de Munain A., Streichenberger N., et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 59 (2006) 905-911
7. Amato A.A. Adults with eosinophilic myositis and calpain-3 mutations. Neurology 70 (2008) 730-731
8. Krahn M., Hanisch F., Goicoechea M., et al. CAPN3 mutations in patients with idiopathic eosinophilic myositis: a predystrophic stage of LGMD2A?. Neuromusc Disord 17 (2007) 791-792 (G.P.4.15) (Abstract)
9. Wardlaw A. Eosinophil trafficking: new answers to old questions. Clin Exp Allergy 34 (2004) 676-679
10. Sugihara R., Kumamoto T., Ito T., et al. Human muscle protein degradation in vitro by eosinophil cationic protein (ECP). Muscle Nerve 24 (2001) 1627-1634
11. Murata K., Sugie K., Takamure M., Fujimoto T., and Ueno S. Eosinophilic major basic protein and interleukin-5 in eosinophilic myositis. Eur J Neurol 10 (2003) 35-38
12. Huang Y., de Morree A., and van Remoortere A. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 17 (2008) 1855-1866
13. Peña Segura J.L., Adrados I., Jiménez Bustos J.M., Cabello A., and López Pisón J. Eosinophilic myositis in a 9 year old boy "Miositis eosinofílica en un niño de 9 años (Spanish). Rev Neurol 33 (2001) 960-963